Investigational drugs for the treatment of osteoarthritis

Bibliography

• Bijlsma JWJ, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011;377(9783):2115-26
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96
   PubMed Web of Science ®Google Scholar
• NIH Consensus Panel. NIH Consensus Statement on total knee replacement December 8-10, 2003. J Bone Joint Surg Am 2004;86-A(6):1328-35
   PubMedGoogle Scholar
• Merx H, Dreinhofer K, Schrader P, et al. International variation in hip replacement rates. Ann Rheum Dis 2003;62(3):222-6
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Felson DT. Osteoarthritis. BMJ 2006;332(7542):639-42
   PubMed Web of Science ®Google Scholar
• Conaghan PG, McQueen FM, Bird P, et al. Update on research and future directions of the OMERACT MRI inflammatory arthritis group. J Rheumatol 2011;38(9):2031-3
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64(4):465-74
   PubMed Web of Science ®Google Scholar
• Wilson N, Sanchez-Riera L, Morros R, et al. Drug utilization in patients with OA: a population-based study. Rheumatology 2015;54(5):860-7
   PubMed Web of Science ®Google Scholar
• Katz JA. COX-2 Inhibition: what we learned—a controversial update on safety data. Pain Med 2013;14:S29-34
   PubMed Web of Science ®Google Scholar
• Mort JS, Billington CJ. Articular cartilage and changes in arthritis: Matrix degradation. Arthritis Res 2001;3(6):337-41
   PubMedGoogle Scholar
• Stanton H, Rogerson FM, East CJ, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005;434(7033):648-52
   PubMed Web of Science ®Google Scholar
• Li W, Du C, Wang H, Zhang C. Increased serum ADAMTS-4 in knee osteoarthritis: a potential indicator for the diagnosis of osteoarthritis in early stages. Genet Mol Res 2014;13(4):9642-9
   PubMed Web of Science ®Google Scholar
• Fosang AJ, Little CB. Drug Insight: aggrecanases as therapeutic targets for osteoarthritis. Nat Clin Pract Rheum 2008;4(8):420-7
   PubMedGoogle Scholar
• Bondeson J, Wainwright SD, Lauder S, et al. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006;8(6):R187-R87
   PubMed Web of Science ®Google Scholar
• Larkin J, Lohr TA, Elefante L, et al. Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis Cartilage 2015;23(8):1254-66
   PubMed Web of Science ®Google Scholar
• Chiusaroli R, Visentini M, Galimberti C, et al. Targeting of ADAMTS5’s ancillary domain with the recombinant mAb CRB0017 ameliorates disease progression in a spontaneous murine model of osteoarthritis. Osteoarthritis Cartilage 2013;21(11):1807-10
   PubMed Web of Science ®Google Scholar
• Chen P, Zhu S, Wang Y, et al. The amelioration of cartilage degeneration by ADAMTS-5 inhibitor delivered in a hyaluronic acid hydrogel. Biomaterials 2014;35(9):2827-36
   PubMed Web of Science ®Google Scholar
• Chockalingam PS, Sun W, Rivera-Bermudez MA, et al. Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage 2011;19(3):315-23
   PubMed Web of Science ®Google Scholar
• Messner K, Maletius W. The long-term prognosis for severe damage to weight-bearing cartilage in the knee: a 14-year clinical and radiographic follow-up in 28 young athletes. Acta Orthop Scand 1996;67(2):165-8
   PubMed Web of Science ®Google Scholar
• Gelber AC, Hochberg MC, Mead LA, et al. Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann Intern Med 2000;133(5):321-8
   PubMed Web of Science ®Google Scholar
• Lohmander LS, Ostenberg A, Englund M, Roos H. High prevalence of knee osteoarthritis, pain, and functional limitations in female soccer players twelve years after anterior cruciate ligament injury. Arthritis Rheum 2004;50(10):3145-52
   PubMed Web of Science ®Google Scholar
• Baragi VM, Becher G, Bendele AM, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheumatism 2009;60(7):2008-18
   PubMed Web of Science ®Google Scholar
• Nara H, Sato K, Naito T, et al. Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach. J Med Chem 2014;57(21):8886-902
   PubMed Web of Science ®Google Scholar
• Nemirovskiy OV, Dufield DR, Sunyer T, et al. Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. Anal Biochem 2007;361(1):93-101
   PubMed Web of Science ®Google Scholar
• Brandt KD, Myers SL, Burr D, Albrecht M. Osteoarthritic changes in canine articular cartilage, subchondral bone, and synovium fifty-four months after transection of the anterior cruciate ligament. Arthritis Rheum 1991;34(12):1560-70
   PubMed Web of Science ®Google Scholar
• Struglics A, Larsson S, Pratta MA, et al. Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage 2006;14(2):101-13
   PubMed Web of Science ®Google Scholar
• Janusz MJ, Hookfin EB, Brown KK, et al. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis. Inflamm Res 2006;55(2):60-5
   PubMed Web of Science ®Google Scholar
• Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007;282(38):27781-91
   PubMed Web of Science ®Google Scholar
• Schnute ME, O’Brien PM, Nahra J, et al. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem Lett 2010;20(2):576-80
   PubMed Web of Science ®Google Scholar
• Settle S, Vickery L, Nemirovskiy O, et al. Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: Confirmation by multivariate analysis that modulation of type ii collagen and aggrecan degradation peptides parallels pathologic changes. Arthritis Rheumatism 2010;62(10):3006-15
   PubMed Web of Science ®Google Scholar
• Krzeski P, Buckland-Wright C, Bálint G, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 2007;9(5):R109
   PubMed Web of Science ®Google Scholar
• Guingamp C, Gegout-Pottie P, Philippe L, et al. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum 1997;40(9):1670-9
   PubMed Web of Science ®Google Scholar
• Ellsworth JL, Berry J, Bukowski T, et al. Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. Osteoarthritis Cartilage 2002;10(4):308-20
   PubMed Web of Science ®Google Scholar
• Ellman MB, Yan D, Ahmadinia K, et al. Fibroblast growth factor control of cartilage homeostasis. J Cell Biochem 2013;114(4):735-42
   PubMed Web of Science ®Google Scholar
• Moore EE, Bendele AM, Thompson DL, et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 2005;13(7):623-31
   PubMed Web of Science ®Google Scholar
• Power J, Hernandez P, Guehring H, et al. Intra-articular injection of rhFGF-18 improves the healing in microfracture treated chondral defects in an ovine model. J Orthop Res 2014;32(5):669-76
   PubMed Web of Science ®Google Scholar
• Dahlberg LE, Flechsenhar K, Dreher D, et al. 309 A randomized, double-blind, placebo-controlled, multicenter study of rhFGF18 administered intraarticularly using single or multiple ascending doses in patients with primary knee osteoarthritis (OA), scheduled for total knee replacement. Osteoarthritis Cartilage 2011;19(Suppl 1):S143
   Google Scholar
• Lohmander LS, Hellot S, Dreher D, et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2014;66(7):1820-31
   PubMed Web of Science ®Google Scholar
• Im H-J, Muddasani P, Natarajan V, et al. Basic fibroblast growth factor stimulates matrix metalloproteinase-13 via the molecular cross-talk between the mitogen-activated protein kinases and protein kinase c delta pathways in human adult articular chondrocytes. J Biol Chem 2007;282(15):11110-21
   PubMed Web of Science ®Google Scholar
• Yan D, Chen D, Cool SM, et al. Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes. Arthritis Res Ther 2011;13(4):R130-R30
   PubMed Web of Science ®Google Scholar
• Chia S-L, Sawaji Y, Burleigh A, et al. Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis. Arthritis Rheumatism 2009;60(7):2019-27
   PubMed Web of Science ®Google Scholar
• Vincent TL. Fibroblast growth factor 2: good or bad guy in the joint? Arthritis Res Ther 2011;13(5):127-7
   PubMed Web of Science ®Google Scholar
• Griffith DL, Keck PC, Sampath TK, et al. Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. Proc Natl Acad Sci U S A 1996;93(2):878-83
   PubMed Web of Science ®Google Scholar
• Wozney JM. Overview of bone morphogenetic proteins. Spine (Phila Pa 1976) 2002;27(16 Suppl 1):S2-8
   PubMed Web of Science ®Google Scholar
• Nishida Y, Knudson CB, Knudson W. Osteogenic Protein-1 inhibits matrix depletion in a hyaluronan hexasaccharide-induced model of osteoarthritis1. Osteoarthritis Cartilage 2004;12(5):374-82
   PubMed Web of Science ®Google Scholar
• Jelic M, Pecina M, Haspl M, et al. Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep. Growth Factors 2001;19(2):101-13
   PubMed Web of Science ®Google Scholar
• Sellers RS, Peluso D, Morris EA. The effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on the healing of full-thickness defects of articular cartilage. J Bone Joint Surg Am 1997;79(10):1452-63
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Pike MC, Jonas BL, et al. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskeletal Disord 2010;11:232-2
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Leeming DJ, Dam EB, et al. Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 2008;16(6):638-46
   PubMed Web of Science ®Google Scholar
• Daghestani HN, Pieper CF, Kraus VB. Soluble macrophage biomarkers indicate inflammatory phenotypes in patients with knee osteoarthritis. Arthritis Rheumatol 2015;67(4):956-65
   PubMed Web of Science ®Google Scholar
• Cao Y, Stannus OP, Aitken D, et al. Cross-sectional and longitudinal associations between systemic, subchondral bone mineral density and knee cartilage thickness in older adults with or without radiographic osteoarthritis. Ann Rheum Dis 2014;73(11):2003-9
   PubMed Web of Science ®Google Scholar
• Castañeda S, Roman-Blas JA, Largo R, Herrero-Beaumont G. Subchondral bone as a key target for osteoarthritis treatment. Biochem Pharmacol 2012;83(3):315-23
   PubMed Web of Science ®Google Scholar
• Yu DG, Yu B, Mao YQ, et al. Efficacy of zoledronic acid in treatment of teoarthritis is dependent on the disease progression stage in rat medial meniscal tear model. Acta Pharmacol Sin 2012;33(7):924-34
   PubMed Web of Science ®Google Scholar
• Laslett LL, Doré DA, Quinn SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis 2012;71(8):1322-8
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Henriksen K, Arnold M, Christiansen C. Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 2008;22(3):137-44
   PubMed Web of Science ®Google Scholar
• Li J, Xie ZG, Xie Y, Dong QR. Calcitonin treatment is associated with less severe osteoarthritis and reduced toll-like receptor levels in a rat model. J Orthop Sci 2014;19(6):1019-27
   PubMed Web of Science ®Google Scholar
• Kyrkos MJ, Papavasiliou KA, Kenanidis E, et al. Calcitonin delays the progress of early-stage mechanically induced osteoarthritis. In vivo, prospective study. Osteoarthritis Cartilage 2013;21(7):973-80
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Henriksen K, et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage 2010;18(2):150-9
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Alexandersen P, et al. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthritis Cartilage 2015;23(4):532-43
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Alexandersen P, et al. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthritis Cartilage 2015;23(4):532-43
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Beaudart C, Neuprez A, Bruyère O. Strontium ranelate in the treatment of knee osteoarthritis: new insights and emerging clinical evidence. Ther Adv Musculoskelet Dis 2013;5(5):268-76
   PubMedGoogle Scholar
• Yu DG, Ding HF, Mao YQ, et al. Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model. Acta Pharmacol Sin 2013;34(3):393-402
   PubMed Web of Science ®Google Scholar
• Cooper C, Reginster JY, Chapurlat R, et al. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr Med Res Opin 2012;28(2):231-9
   PubMed Web of Science ®Google Scholar
• Reginster JY. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind randomised, placebo-controlled trial. Ann Rheum Dis 2014;73(2):e8-8
   PubMed Web of Science ®Google Scholar
• Bruyère O, Cooper C, Pelletier J-P, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Semin Arthritis Rheum 2014;44(3):253-63
   PubMed Web of Science ®Google Scholar
• Pelletier J-P, Roubille C, Raynauld J-P, et al. Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. Ann Rheum Dis 2015;74(2):422-9
   PubMed Web of Science ®Google Scholar
• Alexandersen P, Karsdal MA, Byrjalsen I, Christiansen C. Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric 2010;14(2):236-43
   PubMed Web of Science ®Google Scholar
• Bruyere O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008;67(3):335-9
   PubMed Web of Science ®Google Scholar
• Permuy M, Guede D, López-Peña M, et al. Effects of glucosamine and risedronate alone or in combination in an experimental rabbit model of osteoarthritis. BMC Vet Res 2014;10:97-7
   PubMed Web of Science ®Google Scholar
• Spector TD, Conaghan PG, Buckland-Wright JC, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005;7(3):R625-R33
   PubMed Web of Science ®Google Scholar
• Bingham CO, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheumatism 2006;54(11):3494-507
   PubMed Web of Science ®Google Scholar
• McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014;22(3):363-88
   PubMed Web of Science ®Google Scholar
• Wang X, Hunter D, Xu J, Ding C. Metabolic triggered inflammation in osteoarthritis. Osteoarthritis Cartilage 2015;23(1):22-30
   PubMed Web of Science ®Google Scholar
• McAlindon T, LaValley M, Schneider E, et al. Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial. JAMA 2013;309(2):155-62
   PubMed Web of Science ®Google Scholar
• Sanghi D, Mishra A, Sharma AC, et al. Does vitamin D improve osteoarthritis of the knee: a randomized controlled pilot trial. Clin Orthop Relat Res 2013;471(11):3556-62
   PubMed Web of Science ®Google Scholar
• Jin X, Cicuttini F, Wluka A, et al. OP0296 Vitamin D supplementation for the management of knee osteoarthritis: a two year double blind randomized controlled trial. Ann Rheum Dis 2015;74(Suppl 2):185-5
   PubMed Web of Science ®Google Scholar
• Spector TD, Hart DJ, Nandra D, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40(4):723-7
   PubMed Web of Science ®Google Scholar
• Bos SD, Suchiman HED, Kloppenburg M, et al. Allelic variation at the C-reactive protein gene associates to both hand osteoarthritis severity and serum high sensitive C-reactive protein levels in the GARP study. Ann Rheum Dis 2008;67(6):877-9
   PubMed Web of Science ®Google Scholar
• Goldring MB. Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther 2001;1(5):817-29
   PubMed Web of Science ®Google Scholar
• Botha-Scheepers S, Watt I, Slagboom E, et al. Innate production of tumour necrosis factor alpha and interleukin 10 is associated with radiological progression of knee osteoarthritis. Ann Rheum Dis 2008;67(8):1165-9
   PubMed Web of Science ®Google Scholar
• Magnano MD, Chakravarty EF, Broudy C, et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007;34(6):1323-7
   PubMed Web of Science ®Google Scholar
• Fioravanti A, Fabbroni M, Cerase A, Galeazzi M. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int 2009;29(8):961-5
   PubMed Web of Science ®Google Scholar
• Chevalier X, Ravaud P, Maheu E, et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 2015;74(9):1697-705
   PubMed Web of Science ®Google Scholar
• Verbruggen G, Wittoek R, Cruyssen BV, Elewaut D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis 2012;71(6):891-8
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Russell AS, Chiu P, et al. Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee. Arthritis Res Ther 2012;14(5):R206
   PubMed Web of Science ®Google Scholar
• Urech DM, Feige U, Ewert S, et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNFalpha single-chain Fv antibody (ESBA105) designed for local therapeutic use. Ann Rheum Dis 2010;69(2):443-9
   PubMed Web of Science ®Google Scholar
• Lacy SE, Wu C, Ambrosi DJ, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-IgTM) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs 2015;7(3):605-19
   PubMed Web of Science ®Google Scholar
• Wang SX, Loebbert R, Sampson ER, et al. THU0491 dual variable domain-immunoglobulin (DVD-IG™) ABT-981 simultaneously and dose-dependently inhibits interleukin-1 alpha and -1 beta in subjects with knee osteoarthritis. Ann Rheum Dis 2015;74(Suppl 2):377-8
   Google Scholar
• Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res 2009;61(3):344-52
   Web of Science ®Google Scholar
• Kraus VB, Birmingham J, Stabler TV, et al. Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254). Osteoarthritis Cartilage 2012;20(4):271-8
   PubMed Web of Science ®Google Scholar
• Neidel J, Schroers B, Sintermann F. The effects of high-dose methotrexate on the development of cartilage lesions in a lapine model of osteoarthrosis. Arch Orthop Trauma Surg 1998;117(4-5):265-9
   PubMed Web of Science ®Google Scholar
• Wenham CYJ, Grainger AJ, Hensor EMA, et al. Methotrexate for pain relief in knee osteoarthritis: an open-label study. Rheumatol 2013;52(5):888-92
   PubMed Web of Science ®Google Scholar
• Abou-Raya A, Abou-Raya S, Khadrawe T. Methotrexate in the treatment of symptomatic knee osteoarthritis: randomised placebo-controlled trial. Ann Rheum Dis 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• de Munter W, van der Kraan PM, van den Berg WB, van Lent PLEM. High systemic levels of low-density lipoprotein cholesterol: fuel to the flames in inflammatory osteoarthritis? Rheumatol 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Clockaerts S, Van Osch GJVM, Bastiaansen-Jenniskens YM, et al. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. Ann Rheum Dis 2012;71(5):642-7
   PubMed Web of Science ®Google Scholar
• Kadam UT, Blagojevic M, Belcher J. Statin use and clinical osteoarthritis in the general population: a longitudinal study. J Gen Intern Med 2013;28(7):943-9
   PubMed Web of Science ®Google Scholar
• Miller F, Björnsson M, Svensson O, Karlsten R. Experiences with an adaptive design for a dose-finding study in patients with osteoarthritis. Contemp Clin Trials 2014;37(2):189-99
   PubMed Web of Science ®Google Scholar
• Bernard NJ. Osteoarthritis: Repositioning verapamil – for Wnt of an OA treatment. Nat Rev Rheumatol 2014;10(5):260-0
   PubMedGoogle Scholar
• Nozaki C, Le Bourdonnec B, Reiss D, et al. Delta-opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization. J Pharmacol Exp Ther 2012;342(3):799-807
   PubMed Web of Science ®Google Scholar
• Petersen KL, Iyengar S, Chappell AS, et al. Safety, tolerability, pharmacokinetics, and effects on human experimental pain of the selective ionotropic glutamate receptor 5 (iGluR5) antagonist LY545694 in healthy volunteers. Pain 2014;155(5):929-36
   PubMed Web of Science ®Google Scholar
• Chappell AS, Iyengar S, Lobo ED, Prucka WR. Results from clinical trials of a selective ionotropic glutamate receptor 5 (iGluR5) antagonist, LY5454694 tosylate, in 2 chronic pain conditions. Pain 2014;155(6):1140-9
   PubMed Web of Science ®Google Scholar
• Cucchi P, Meini S, Bressan A, et al. MEN16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B2 receptor. In vitro pharmacology and molecular characterization. Eur J Pharmacol 2005;528(1–3):7-16
   PubMed Web of Science ®Google Scholar
• Cialdai C, Giuliani S, Valenti C, et al. Effect of Intra-articular 4-(S)-Amino-5-(4-{4-[2,4-dichloro-3-(2,4-dimethyl-8-quinolyloxymethyl)phenylsulfonamido]-tetrahydro-2H-4-pyranylcarbonyl} piperazino)-5-oxopentyl](trimethyl)ammonium chloride hydrochloride (MEN16132), a kinin B2 receptor antagonist, on nociceptive response in monosodium iodoacetate-induced experimental osteoarthritis in rats. J Pharmacol Exp Ther 2009;331(3):1025-32
   PubMed Web of Science ®Google Scholar
• Denoble AE, Huffman KM, Stabler TV, et al. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci U S A 2011;108(5):2088-93
   PubMed Web of Science ®Google Scholar
• Leung YY, Yao Hui LL, Kraus VB. Colchicine—Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 2015. [Epub ahead of print]
   Google Scholar
• Leung Y-Y, Thumboo J, Wong BS, et al. Colchicine effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): study protocol for a randomized controlled trial. Trials 2015;16:200
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs 2014;74(6):619-26
   PubMed Web of Science ®Google Scholar
• Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 2011;152(10):2248-58
   PubMed Web of Science ®Google Scholar
• Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010;363(16):1521-31
   PubMed Web of Science ®Google Scholar
• Balanescu AR, Feist E, Wolfram G, et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis 2014;73(9):1665-72
   PubMed Web of Science ®Google Scholar
• Glasson SS, Askew R, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005;434(7033):644-8
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Bay-Jensen AC, Lories RJ, et al. The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments? Ann Rheum Dis 2014;73(2):336-48
   PubMed Web of Science ®Google Scholar
• Knoop J, van der Leeden M, Thorstensson CA, et al. Identification of phenotypes with different clinical outcomes in knee osteoarthritis: Data from the osteoarthritis initiative. Arthritis Care Res 2011;63(11):1535-42
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Christiansen C, Ladel C, et al. Osteoarthritis--a case for personalized health care? Osteoarthritis Cartilage 2014;22(1):7-16
   PubMed Web of Science ®Google Scholar
• Mazières B, Garnero P, Guéguen A, et al. Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH cohort. Ann Rheum Dis 2006;65(3):354-9
   PubMed Web of Science ®Google Scholar
• Garnero P, Aronstein WS, Cohen SB, et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the knee osteoarthritis structural arthritis randomized clinical trial. Osteoarthritis Cartilage 2008;16(6):660-6
   PubMed Web of Science ®Google Scholar
• Garnero P, Ayral X, Rousseau J-C, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheumatism 2002;46(10):2613-24
   PubMed Web of Science ®Google Scholar
• Dam EB, Loog M, Christiansen C, et al. Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther 2009;11(4):R115-R15
   PubMed Web of Science ®Google Scholar
• Zuo H, Jiang L, Qu N, et al. The biomarkers changes in serum and the correlation with quantitative MRI markers by histopathologic evaluation of the cartilage in surgically-induced osteoarthritis rabbit model. PLoS One 2015;10(4):e0124717
   Google Scholar